Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study.

Benson AB 3rd, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G, Cunningham J, Houghton B, Ross M, Memon K, Andrews J, Fleming CJ, Herman J, Nimeiri H, Lewandowski RJ, Salem R.

Eur J Cancer. 2013 Oct;49(15):3122-30. doi: 10.1016/j.ejca.2013.05.012. Epub 2013 Jun 15.

PMID:
23777743
2.

Radioembolisation with Yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases.

Bester L, Meteling B, Pocock N, Saxena A, Chua TC, Morris DL.

J Med Imaging Radiat Oncol. 2013 Feb;57(1):72-80. doi: 10.1111/j.1754-9485.2012.02459.x. Epub 2012 Oct 9.

PMID:
23374558
3.

Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.

Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, De Keukeleire K, Verslype C, Defreyne L, Van Cutsem E, Delatte P, Delaunoit T, Personeni N, Paesmans M, Van Laethem JL, Flamen P.

J Clin Oncol. 2010 Aug 10;28(23):3687-94. doi: 10.1200/JCO.2010.28.5643. Epub 2010 Jun 21.

PMID:
20567019
4.

90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.

Fidelman N, Kerlan RK Jr, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP.

J Gastrointest Cancer. 2014 Jun;45(2):168-80. doi: 10.1007/s12029-013-9566-7.

PMID:
24448917
5.

Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.

Memon K, Kuzel TM, Vouche M, Atassi R, Lewandowski RJ, Salem R.

Melanoma Res. 2014 Jun;24(3):244-51. doi: 10.1097/CMR.0000000000000051.

PMID:
24638152
6.

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.

Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F; Italian Society of Locoregional Therapies in Oncology (SITILO)..

Br J Cancer. 2010 Jul 27;103(3):324-31. doi: 10.1038/sj.bjc.6605770. Epub 2010 Jul 13.

7.

Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.

Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R.

Radiology. 2008 May;247(2):507-15. doi: 10.1148/radiol.2472062029. Epub 2008 Mar 18.

PMID:
18349311
8.

Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy.

Golfieri R, Mosconi C, Giampalma E, Cappelli A, Galaverni MC, Pettinato C, Renzulli M, Monari F, Mazzarotto R, Pinto C, Angelelli B.

Radiol Med. 2015 Aug;120(8):767-76. doi: 10.1007/s11547-015-0504-6. Epub 2015 Feb 13.

PMID:
25678128
9.

90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.

Hickey R, Lewandowski RJ, Prudhomme T, Ehrenwald E, Baigorri B, Critchfield J, Kallini J, Gabr A, Gorodetski B, Geschwind JF, Abbott A, Shridhar R, White SB, Rilling WS, Boyer B, Kauffman S, Kwan S, Padia SA, Gates VL, Mulcahy M, Kircher S, Nimeiri H, Benson AB, Salem R.

J Nucl Med. 2016 May;57(5):665-71. doi: 10.2967/jnumed.115.166082. Epub 2015 Dec 3.

10.

Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases.

Cianni R, Urigo C, Notarianni E, Saltarelli A, D'Agostini A, Iozzino M, Dornbusch T, Cortesi E.

Radiol Med. 2010 Jun;115(4):619-33. doi: 10.1007/s11547-010-0496-1. Epub 2010 Jan 20. English, Italian.

PMID:
20091135
11.

Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.

Michl M, Haug AR, Jakobs TF, Paprottka P, Hoffmann RT, Bartenstein P, Boeck S, Haas M, Laubender RP, Heinemann V.

Oncology. 2014;86(1):24-32. doi: 10.1159/000355821. Epub 2013 Dec 21.

PMID:
24401529
12.

Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.

Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A, Morris DL.

J Vasc Interv Radiol. 2012 Jan;23(1):96-105. doi: 10.1016/j.jvir.2011.09.028. Epub 2011 Nov 12.

PMID:
22079516
13.

Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.

Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, Schmidt GP, Ashoori N, Reiser MF, Jakobs TF.

Cardiovasc Intervent Radiol. 2012 Apr;35(2):334-42. doi: 10.1007/s00270-011-0248-1. Epub 2011 Aug 17.

PMID:
21847708
14.

Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases.

Smits ML, van den Hoven AF, Rosenbaum CE, Zonnenberg BA, Lam MG, Nijsen JF, Koopman M, van den Bosch MA.

PLoS One. 2013 Jul 24;8(7):e69448. doi: 10.1371/journal.pone.0069448. Print 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/559e04cc-b09c-4b5c-9405-56837f6d5627.

15.

Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.

Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, van Het Schip AD, Zonnenberg BA.

Lancet Oncol. 2012 Oct;13(10):1025-34. doi: 10.1016/S1470-2045(12)70334-0. Epub 2012 Aug 22. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464.

PMID:
22920685
16.

Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.

Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, La Fougere C, Murthy R, Helmberger TK, Reiser MF.

J Vasc Interv Radiol. 2008 Aug;19(8):1187-95. doi: 10.1016/j.jvir.2008.05.013. Epub 2008 Jun 27.

PMID:
18656012
17.

Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.

Abdelmaksoud MH, Louie JD, Hwang GL, Kothary N, Minor DR, Sze DY.

J Vasc Interv Radiol. 2012 Mar;23(3):323-30.e1. doi: 10.1016/j.jvir.2011.11.007. Epub 2012 Jan 25.

PMID:
22277275
18.

Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres.

Melucci E, Cosimelli M, Carpanese L, Pizzi G, Izzo F, Fiore F, Golfieri R, Giampalma E, Sperduti I, Ercolani C, Sciuto R, Mancini R, Garufi C, Diodoro MG, Mottolese M; Italian Society of Locoregional Therapies in Oncology (S.I.T.I.L.O.)..

J Exp Clin Cancer Res. 2013 Mar 6;32:13. doi: 10.1186/1756-9966-32-13.

19.

Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization.

Schonewolf CA, Patel B, Gensure RH, Narra V, Haffty BG, Nosher JL, Jabbour SK.

Am J Clin Oncol. 2014 Jun;37(3):234-40. doi: 10.1097/COC.0b013e318277d610.

PMID:
23275270
20.

Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.

Burgmans MC, Kao YH, Irani FG, Dames EL, Teo TK, Goh AS, Chow PK, Tay KH, Lo RH.

J Vasc Interv Radiol. 2012 Oct;23(10):1294-301. doi: 10.1016/j.jvir.2012.07.009. Epub 2012 Aug 24.

PMID:
22922039

Supplemental Content

Support Center